Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Aaron Logan, MD
- Target Recruit Count
- 36
- Registration Number
- NCT06160791
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06079879
- Locations
- 🇨🇳
Anhui Provincial Hospital ( Site 3513), Hefei, Anhui, China
🇨🇳Peking University Third Hospital-Hematology ( Site 3502), Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital Of Fujian Medical University ( Site 3525), Quanzhou, Fujian, China
MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 62
- Registration Number
- NCT06075225
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chendu, Sichuan, China
Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 49
- Registration Number
- NCT06008808
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-12-16
- Target Recruit Count
- 1
- Registration Number
- NCT05998395
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-11-18
- Target Recruit Count
- 145
- Registration Number
- NCT05998408
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 118
- Registration Number
- NCT05980806
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇧🇪UZ Gent, Gent, Belgium
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 225
- Registration Number
- NCT05936359
- Locations
- 🇮🇹
Aou Policlinico S. Orsola-Malpighi Bologna, Bologna, Italy
🇦🇺Royal Brisbane and Women'S Hospital, Herston, Queensland, Australia
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Tianjin Medical University General Hospital
- Registration Number
- NCT05909943
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
- Conditions
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 94
- Registration Number
- NCT05870475
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.